European Medicines Agency grants Orphan Drug Designation to Zydus Cadila’s Saroglitazar Mg

Orphan Drug status in Europe is given to medicines with the potential to be safe and effective treatments for rare, life-threatening, or chronically debilitating conditions affecting no more than 5 people in 10,000 people.